key: cord-0918917-8si3i2ob
authors: Di Giambenedetto, Simona; Del Giacomo, Paola; Ciccullo, Arturo; Porfidia, Angelo; De Matteis, Giuseppe; Cianci, Rossella; De Vito, Francesco; Dusina, Alex; Borghetti, Alberto; Tumbarello, Mario
title: SARS-CoV-2 infection in a highly experienced person living with HIV
date: 2020-06-10
journal: AIDS
DOI: 10.1097/qad.0000000000002572
sha: 58e5ea84daa61e02d0dc0eefc35ea027351b8b30
doc_id: 918917
cord_uid: 8si3i2ob

nan

Dear Editor, since the first cases reported in December 2019 in Wuhan (Hubei, China), [1] COVID-19 has spread all over the world, until reaching the state of pandemic, as recognized by the World Health Organization (WHO). [2] Patients infected by the SARS-CoV-2, the etiological agent of COVID-19, showed symptoms of fever, cough and dyspnoea, lymphopenia, and interstitial pneumonia in radiological examinations. [3, 4] About 20% of cases develop severe diseases, with life-threatening complications such as respiratory failure, shock, and multiple organs dysfunction. [5] Given the correlation with lymphopenia, it was thought that people living with HIV could have an increased risk of contracting COVID-19 and, moreover, of manifesting a severe form of the disease. A joint statement from EACS and BHIVA [6] clarified that, with current data, there is no clear evidence of a higher COVID-19 infection rate or different disease course in people with HIV than in HIVnegative people. To the best of our knowledge, only one case was reported of HIV and COVID-19 co-infection in a newly-diagnosed 61-years old man in China. [7] We hereby report the case of a 75 years old male patient, with a history of 23 years since HIV diagnosis. The patient did not have an AIDS-defining event in his clinical history, his nadir CD4+ <250), a d-dimer of 2232 ng/mL (RV <500) and a leukocyte count of 6340/mm3, with a lymphocites' count of 1380/mm3. Chest X-rays showed bilateral signs of interstitial pneumonia with ground-glass opacity in the anterior segment of the upper right lobe. Antiretroviral therapy was hence modified, discontinuing the single tablet regimen (STR) of rilpivirine/emtricitabine/tenofovir alafenamide and starting a STR with darunavir/cobicistat/emtricitabine/tenofovir alafenamide.

Hydroxycloroquine was also started for the treatment of COVID-19 along with antibiotic therapy with azithromycin. In the days immediately following, clinical conditions worsened, with persistent fever and worsening dyspnea, requiring a progressive increase in oxygen supplementation up to a Starting on April 4th, we observed a progressive improvement in clinical conditions, with the resolution of fever and improvement of respiratory parameters and gas exchange. Oxygen supplementation was rapidly discontinued. Two consecutive molecular essays of naso-pharyngeal swabs on April 6th and 7th tested negative, and the patient was discharged on April 9th in good clinical conditions. Our work describes one of the first reported cases of COVID-19 in a person living with HIV. In our patient, antiretroviral therapy was switched to a PI-based strategy, based on the evidence that some PIs have "in-vitro" activity against SARS-CoV-2, [8] although clinical trials failed to show significant advantages of PIs in severe forms of COVID-19. [9] The patient failed to improve after initial therapy with hydroxycloroquine and azithromycin was started; as a matter of fact, the association of these two drugs, both of whom are potentially cardiotoxic, caused the observed Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. conduction disorder. The improvement, meanwhile, was observed following administration of sarilumab, a humanized anti-human IL-6 receptor antibody of the IgG1 subclass, currently investigated as a potential therapeutic agent against COVID-19. In our case, sarilumbab was administered at a reduced dosage given the history of HBV infection; no hepatitis flares were observed during hospitalization. It is also worth mentioning that, during hospitalization, the patient was administered low molecular weight heparin (LMWH) at prophylactic dose, following initial reports on the potential benefit of anticoagulant therapy in SARS-CoV-2 infections. Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

Covid-19 -Navigating the Uncharted

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Accessed on

Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China

Remdesivir,lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication invitro